Boston Family Office’s Teva Pharmaceuticals TEVA Stock Holding History

Boston Family Office’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-72,929	Closed	-$2.64M	–	245
2016 Q4	$2.64M	Sell	72,929 -35,590	-33%	-$1.42M	0.34%	87
2016 Q3	$4.99M	Sell	108,519 -1,530	-1%	-$79.8K	0.65%	49
2016 Q2	$5.53M	Hold	110,049	–	–	0.72%	45
2016 Q1	$5.89M	Sell	110,049 -242	-0.2%	-$14.2K	0.78%	41
2015 Q4	$7.24M	Sell	110,291 -100	-0.1%	-$6.18K	0.99%	30
2015 Q3	$6.23M	Hold	110,391	–	–	0.87%	32
2015 Q2	$6.52M	Sell	110,391 -1,135	-1%	-$70K	0.82%	35
2015 Q1	$6.95M	Hold	111,526	–	–	0.86%	34
2014 Q4	$6.41M	Hold	111,526	–	–	0.8%	37
2014 Q3	$6M	Sell	111,526 -76	-0.1%	-$4.03K	0.77%	39
2014 Q2	$5.85M	Sell	111,602 -2,390	-2%	-$122K	0.74%	42
2014 Q1	$6.02M	Hold	113,992	–	–	0.8%	38
2013 Q4	$4.57M	Sell	113,992 -7,565	-6%	-$298K	0.6%	56
2013 Q3	$4.59M	Sell	121,557 -6,570	-5%	-$256K	0.65%	49
2013 Q2	$5.02M	Buy	+128,127	New	+$4.99M	0.76%	41

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Boston Family Office's TEVA Position: Q1 2017 in Review

Boston Family Office sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 72,929 shares — an estimated $2.64M sold.

Boston Family Office first reported a position in TEVA in Q2 2013 and held it in 15 quarters. The position peaked at $7.24M in Q4 2015. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

Boston Family Office reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Boston Family Office sold 72,929 Teva Pharmaceuticals shares in Q1 2017, an estimated $2.64M.
Boston Family Office first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 15 quarters.
Boston Family Office's Teva Pharmaceuticals position peaked at $7.24M in Q4 2015.
686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Boston Family Office's 13F filing for Q1 2017, filed 5 May 2017.